Biocon
Sangbit Paul is an Executive at Biocon since May 2022, with prior experience as a Drug Safety Associate at WIPRO from May 2021 to November 2021, where responsibilities included case processing for US and Italy Covid-19 Pfizer vaccine cases. Sangbit Paul holds a Master’s degree in Pharmacy with a specialization in Pharmaceutics and Drug Design from GITAM Deemed University (2019-2021) and a Bachelor’s degree in Pharmacy from Siksha 'O' Anusandhan University (2015-2019). Educational background includes attending St. Stephen's School in DumDum.
This person is not in any teams
This person is not in any offices
Biocon
21 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.